Document is current
Any future updates will be listed below
-
Authors
Tucci, Francesca
Galimberti, Stefania
Naldini, Luigi https://orcid.org/0000-0002-7835-527X
Valsecchi, Maria Grazia
Aiuti, Alessandro https://orcid.org/0000-0002-5398-1717
-
Funding
Funding for this research was provided by:
Fondazione Telethon (SR-TIGET core grant, SR-TIGET core grant, SR-TIGET core grant)
- License Information
-
More Information
Article History
Received: 6 June 2021
Accepted: 8 February 2022
First Online: 14 March 2022
Competing interests
: A.A. is PI of clinical trials sponsored by Orchard Therapeutics, which licensed gene therapy products for ADA-SCID, WAS, MLD, Beta-thalassemia, and MPS originally developed at SR-TIGET. A.A. is a member of Committee for Advanced Therapies (CAT) and his views are personal and may not be understood or quoted as being made on behalf of the European Medicines Agency (EMA). L.N. is an inventor on pending and issued patents on LV technology filed by the Salk Institute, Cell Genesys, Telethon Foundation, and/or San Raffaele Scientific Institute. The other authors have no competing interests.
